Vicky Cuylaerts

Vicky Cuylaerts

Auto-generated profile, based on publicly available information

Vicky Cuylaerts

Institute of Tropical Medicine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
IBIrith De Baetselier
Irith De Baetselier
HSHilde Smet
Hilde Smet
SASaïd Abdellati
Saïd Abdellati
BDBénédicte De Deken
Bénédicte De Deken
VCVicky Cuylaerts
Vicky Cuylaerts
TCTania Crucitti
Tania Crucitti
Objectives: Pre-exposure prophylaxis (PrEP) users are screened bi-annual for sexually transmitted infections (STIs). A novel device, called the Colli-Pee, collects first-void urine in a standardised way and the collector tube can be easily delivered by regular post to a certified laboratory. The aim of the study was a one-to-one comparison between the STI test results obtained with the urine collected in the clinic, versus urine collected at home in a real-life setting by Men who have Sex with Men (MSM) in Belgium. The user-friendliness and acceptability of the Colli-Pee device by the users was also evaluated.Design: A single-site nested substudy in a prospective PrEP demonstration project (Be-PrEP-ared) among MSM in Belgium.Participants: A total of 473 home-based samples from 213 MSM were received with a mean age of 38.5 years.Interventions: Participants were requested to collect a urine sample at home using the Colli-Pee device and to send it to the laboratory via regular mail.Primary and secondary outcome measures: The presence ofChlamydia trachomatis(CT), Neisseria gonorrhoeae(NG), Mycoplasma genitalium(MG) andTrichomonas vaginalis(TV) was determined using molecular amplification assays. Agreement between test results of samples collected at the clinic and collected at home were evaluated using Cohen’s kappa statistic.Results: TV was not detected. A very good to almost perfect agreement was found for CT, NG and MG of κ=0.75, 0.87 and 0.85, respectively. Using the Colli-Pee device only one low positive CT and two MG infections were missed, however, three additional CT, two NG and six MG infections were detected.Conclusions: The Colli-Pee device is a feasible and convenient way to collect urine at home for STI testing. This may be particularly relevant for populations that need frequent STI testing, such as PrEP users and patients who prefer home-sampling.Trial registration number: NCT02552914; Pre-results.

20 December 2018 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
IBIrith De Baetselier
Irith De Baetselier
ATAchilleas Tsoumanis
Achilleas Tsoumanis
RVRuth Verbrugge
Ruth Verbrugge
BDBénédicte De Deken
Bénédicte De Deken
HSHilde Smet
Hilde Smet
TCTania Crucitti
Tania Crucitti
The number of cases of Lymphogranuloma venereum (LGV) is increasing in Europe. The described epidemic is mostly confined to HIV positive men who have sex with men (MSM). However, dissemination of LGV from HIV positive to HIV negative MSM could take place due to the implementation of pre-exposure prophylaxis (PrEP) and subsequent possible decrease in condom use. We describe here the LGV epidemiology in Belgium before the PrEP-era, starting from 2011 up to the end of the first half of 2017. A descriptive analysis of the socio-demographic and clinical characteristics of all LGV cases was performed. Fisher’s exact test was used to compare symptomatic to asymptomatic patients. Logistic regression models were used to check for trends over time for: number of LGV cases, HIV status and symptoms. The number of LGV cases rose by a factor four, from 21 in 2011 to 88 in 2016, and regression models showed a positive trend estimate of 14% increase per half year (p < 0.001). LGV decreased among HIV positive cases (odds ratio (OR): 0.79, p < 0.001) and increased among HIV negative cases (OR: 1.27, p < 0.001). In addition, a rise in the number of asymptomatic LGV cases (6.7%) was observed (OR:1.39, p = 0.047). Asymptomatic cases were also less likely to be HIV (p = 0.046) or Hepatitis C positive (p = 0.027). The rise of LGV in HIV negative MSM has now been documented. If we aim to halt the epidemic in HIV negative MSM, future public health strategies should include LGV testing of all Chlamydia trachomatis positive samples from MSM.

11 September 2019 in F1000Research
Verified
Journal Article
Open access
PDF file
CDChristophe Van Dijck
Christophe Van Dijck
VCVicky Cuylaerts
Vicky Cuylaerts
PSPiet Sollie
Piet Sollie
ASAnna Spychala
Anna Spychala
IBIrith De Baetselier
Irith De Baetselier
CKChris Kenyon
Chris Kenyon
Background: The oropharynx plays a major role in the development and spread of antimicrobial resistant Neisseria gonorrhoeae among men who have sex with men. Trials are currently assessing the efficacy of bactericidal mouthwashes as possible therapeutic or preventive options against these pharyngeal gonococcal infections. Controlled clinical trials require the use of a placebo mouthwash without anti-gonococcal activity. So far, no such mouthwash has been described. We describe the development of a mouthwash for this purpose. Methods: The in vitro anti-gonococcal activity of Corsodyl®, Listerine Cool Mint®, Biotene®, phosphate buffered saline and six in-house placebo mouthwashes was evaluated. Three gonococcal isolates from patients with pharyngeal infection were exposed to the mouthwashes for a duration ranging from 30 seconds to 60 minutes. Isolates were then plated onto blood agar (5% horse blood) and incubated for 24 hours (5-7% CO2, 35 ± 2°C). Growth of N. gonorrhoeae was scored on a five-point scale (0 to 4). All experiments were conducted in duplicate. Results: Corsodyl® and Listerine Cool Mint® were bactericidal to all isolates. For the other mouthwashes, the median growth score after 60 minutes of exposure was 4 (interquartile range 4-4) for phosphate buffered saline; 1 (interquartile range 1-3) for Biotene®; and ranged between 0 and 2 for the in-house composed mouthwashes. An in-house composed mouthwash (Placebo 6) performed best, with a growth score of 2 (interquartile range 2-3). Conclusions: All of the evaluated potential placebo mouthwashes were bacteriostatic after gonococcal exposure of 30 to 60 minutes. In-house composed Placebo 6 showed less inhibition on gonococcal growth than Biotene® and the other in-house placebos and demonstrates, in our opinion, a good trade-off between anti-gonococcal properties and taste.

17 February 2020 in F1000Research
Verified
Journal Article
Open access
PDF file
CDChristophe Van Dijck
Christophe Van Dijck
VCVicky Cuylaerts
Vicky Cuylaerts
PSPiet Sollie
Piet Sollie
ASAnna Spychala
Anna Spychala
IBIrith De Baetselier
Irith De Baetselier
CKChris Kenyon
Chris Kenyon
Background: The oropharynx plays a major role in the development and spread of antimicrobial resistant Neisseria gonorrhoeae among men who have sex with men. Trials are currently assessing the efficacy of bactericidal mouthwashes as possible therapeutic or preventive options against these pharyngeal gonococcal infections. Controlled clinical trials require the use of a placebo mouthwash without anti-gonococcal activity. So far, no such placebo mouthwash has been described. We describe the development of a mouthwash for this purpose. Methods: The in vitro anti-gonococcal activity of Corsodyl®, Listerine Cool Mint®, Biotene®, phosphate buffered saline and six in-house placebo mouthwashes was evaluated. Three gonococcal isolates from patients with pharyngeal infection were exposed to the mouthwashes for a duration ranging from 30 seconds to 60 minutes. Isolates were then plated in duplicate onto blood agar (5% horse blood) and incubated for 24 hours (5-7% CO 2, 35 ± 2°C). Growth of N. gonorrhoeae was scored on a five-point scale (0 = no growth, to 4 = confluent growth of colonies). Results: Corsodyl® and Listerine Cool Mint® were bactericidal to all isolates. For the other mouthwashes, the median growth score after 60 minutes of exposure was 4 (interquartile range 4-4) for phosphate buffered saline; 1 (interquartile range 1-3) for Biotene®; and ranged between 0 and 2 for the in-house composed mouthwashes. An in-house composed mouthwash (Placebo 6) performed best, with a growth score of 2.5 (interquartile range 1-3). Conclusions: All the evaluated potential placebo mouthwashes were bacteriostatic after gonococcal exposure of 30 to 60 minutes. In-house composed Placebo 6 showed less inhibition on gonococcal growth than Biotene® and the other in-house placebos and demonstrates, in our opinion, a good trade-off between anti-gonococcal properties and taste.

21 February 2019 in African Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
VCVicky Cuylaerts
Vicky Cuylaerts
IBIrith De Baetselier
Irith De Baetselier
Claude Mambo MuvunyiClaude Mambo Muvunyi
Claude Mambo Muvunyi
LMLambert Mwambarange
Lambert Mwambarange
HSHilde Smet
Hilde Smet
TCTania Crucitti
Tania Crucitti
Background: The Presto combined qualitative real-time assay for Chlamydia trachomatis and Neisseria gonorrhoeae (Presto CT/NG PCR assay) is appealing for developing countries, because it can be used with multiple DNA extraction methods and polymerase chain reaction (PCR) platforms.Objectives: The objective of the study was to implement and evaluate the Presto CT/NG PCR assay at the National Reference Laboratory (NRL) in Kigali, Rwanda, where no real-time PCR assays for the detection of C. trachomatis or N. gonorrhoeae were available.Methods: The Presto CT/NG PCR assay was first evaluated at the Institute of Tropical Medicine (ITM) in Antwerp, Belgium. Next, NRL laboratory technicians were trained to use the assay on their ABI PRISM 7500 real-time PCR instrument and their competencies were assessed prior to trial initiation. During the trial, endocervical swabs were tested at the NRL, with bi-monthly external quality control testing monitored by the ITM. The final NRL results were evaluated against extended gold standard testing at the ITM, consisting of the Abbott m2000 RealTime System with confirmation of positive results by an in-house real-time PCR assay for C. trachomatis or N. gonorrhoeae.Results: Of the 192 samples analysed using the Presto assay at the NRL, 16 samples tested positive for C. trachomatis and 17 tested positive for N. gonorrhoeae; four of these were infected with both. The sensitivity and specificity of the Presto assay were 93.3% (95% confidence interval [CI]: 68.1% – 99.8%) and 99.4% (95% CI: 96.8% – 100%) for C. trachomatis and 100% (95% CI: 76.8% – 100%) and 98.8% (95% CI: 95.8% – 99.9%) for N. gonorrhoeae.Conclusion: C. trachomatis and N. gonorrhoeae testing with the Presto assay was feasible in Kigali, Rwanda, and good performance was achieved.

15 March 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
RNRodríguez Nadia
Rodríguez Nadia
CVCuylaerts Vicky
Cuylaerts Vicky
SRSardiñas Ruxana
Sardiñas Ruxana
GOGutiérrez Oderay
Gutiérrez Oderay
SYSoto Yudira
Soto Yudira
IBIrith De Baetselier
Irith De Baetselier
To The Editor—We read with interest the recent publication by Prazuck et al. concerning the effectiveness of a pooled methodology to detect Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) in the 3 anatomical sites among men who have sex with men (MSM) using the Allplex STI Essential Assay (Seegene, Seoul, South Korea) [ 1]. Due to the increasing evidence that pooling of samples to detect sexually transmitted infections (STIs) is cost-effective with limited reduction in performance characteristics, we decided to validate a similar pooling method in Cuba. Although extragenital sampling among MSM is recommended to curb the STI epidemic in this population, extragenital sampling for STIs is still not recommended in Cuba. One of the main reasons is the additional cost of extragenital STI testing. As such, a pooling methodology that can be used in Cuba is urgently needed. STI pooling methodologies described in the literature mostly use American platforms such as Abbott (Abbott Technologies, Illinois, USA), Aptima (Hologic, San Diego, California, USA), and GeneXpert (Cepheid, California, USA), which are unfortunately not available in Cuba [ 2–5]. The Allplex STI Essential Assay pooling method described by Prazuck et al. uses Seegene-specific instruments or the CFX96 real-time polymerase chain reaction (PCR) instrument from Bio-Rad (CA, USA), which is also difficult to purchase in Cuba.